Clinical trials: Resistant Depression, Treatment
Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality…
- Conditions
- Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder, Treatment-resistant Bipolar Depression, Major Depressive Disorder (MDD)
- Trial name
- KET-DBT (NCT07569198)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Joshua Rosenblat
Treatment Resistant Major Depression
Establishing Mobile Transcranial Magnetic Stimulation
In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving…
- Trial name
- TMS (NCT06748209)
- Testing
- Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina
Depressive Disorder, Treatment-Resistant
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
This pilot study aims to identify predictors of response to intranasal ketamine treatment in patients with treatment-resistant depression.
- Trial name
- NCT04216888
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dan Iosifescu
Suicidal Ideation, Major Depressive Disorder
The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression
Suicide attempts are a serious concern worldwide. Currently, existing drugs take about three weeks to show effect on suicidal thoughts and drives.
- Conditions
- Suicidal Ideation, Major Depressive Disorder, Healthy Participants
- Trial name
- NCT02037503
- Testing
- Ketamine, Saline
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Electroencephalography
Intermittent Theta Burst Stimulation on Anhedonia in Depression
Study comparing the efficacy of two TMS patterns (intermittent theta-burst stimulation, iTBS, and repetitive transcranial magnetic stimulation, rTMS) in treating anhedonia and their associated brain network mechanisms.
- Conditions
- Depression, Electroencephalography, Transcranial Magnetic Stimulation
- Trial name
- NCT06552026
- Testing
- repeated transcranial magnetic stimulation
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Anhui Medical University
Major Depressive Disorder
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)
To confirm the safety and efficacy of the NCP System in treating patients in a nmajor depressive episode.
- Trial name
- NCT00533832
- Testing
- vagus nerve stimulation (VNS)
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Cyberonics, Inc.
Depression
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
- Trial name
- NCT01114698
- Testing
- Venlafaxine XR, JNJ26489112
- Where
- 14 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder (MDD), Major Depressive Episode
Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study
The goal of this observational study is to learn about remote mental health monitoring technology for adults with treatment-resistant depression.
- Conditions
- Major Depressive Disorder (MDD), Major Depressive Episode, Treatment-Resistant Major Depressive Disorder
- Trial name
- NCT06732089
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Unity Health Toronto
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression; Bipolar Disorder
Comparing Different Patterns of rTMS in Major Depression
This trial will compare the trajectories of improvement for three different patterns of twice-daily rTMS in major depression: two daily sessions of dorsomedial prefrontal rTMS delivered at 0 min vs. 30 min vs. 60 min intervals.
- Trial name
- NCT02778035
- Testing
- Dorsomedial prefrontal rTMS
- Where
- 2 sites in Canada
- Volunteers
- 180 people
- Sponsor
- University Health Network, Toronto
Major Depression
Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD.
This is a single-center, randomized, double-blind, sham-controlled, crossover exploratory clinical trial designed to evaluate the therapeutic effects of task-specific, biomarker-driven HD-ctACS on treatment-resistant depression…
- Trial name
- NCT07184697
- Testing
- HD ctACS
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Depressive Disorder, Major
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression
The goals of this study are: 1) to investigate the efficacy of combining ketamine with intensive cognitive behavioral therapy (CBT) to sustain the antidepressant effects of ketamine; and 2) to determine ketamine's delayed effects…
- Trial name
- NCT03027362
- Testing
- Cognitive behavioral therapy (CBT) and medication, Psychoeducation and medication
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Late Life Depression
A Breathing-Based Meditation Intervention for Patients With Treatment Resistant Late Life Depression
Late-life depression affects 2-8% of seniors and causes high rates of caregiver distress and risk of suicide. To exacerbate the problem, antidepressants, the cornerstone of therapy, are resistant in 55-80% of this population.
- Trial name
- NCT03368560
- Testing
- Sudarshan Kriya Yoga
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia, Treatment Resistant Depression
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
- Conditions
- Schizophrenia, Treatment Resistant Depression, Aging, Premature
- Trial name
- NCT05838560
- Testing
- Dasatinib, quercetin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression
In this study patients with treatment resistant depression, as defined by Harold Sackeim, is subjected to daily sessions, for eight weeks, with Pulsating ElectroMagnetive Treatment (PEMF).
- Trial name
- PEMFII (NCT01353092)
- Testing
- Re5 Pulsating ElectroMagnetic Fields, Re5 Pulsating ElectroMagnetic Fields (PEMF)
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Hillerod Hospital, Denmark
Treatment Resistant Depression
D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression
This is a two-stage experiment; the first stage is an open label trial in which participants receive six intravenous (IV) treatments of ketamine. The second stage includes participants that responded to ketamine (i.e.
- Trial name
- NCT02772211
- Testing
- Ketamine, D-cycloserine
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Treatment Resistant Depression
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled.
- Trial name
- ENLIGHTEN (NCT05113771)
- Testing
- Liafensine
- Where
- 45 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia, Treatment Resistant Depression (TRD)
Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment
The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments.
- Conditions
- Schizophrenia, Treatment Resistant Depression (TRD), Bipolar Disorder (BD), Catatonia
- Trial name
- BIO-INM (NCT07741981)
- Testing
- Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Centre Hospitalier St Anne